reported non-significant results (alendronate: HR 1.24, 95% CI 0.84–1.83; zoledronic acid: HR 1.15, 95% CI 0.70–1.89) [ 23 ] and (2) a meta-analysis of individual participant data exhibited borderline significance (reduction in recurrence: RR 0.94, 95% CI 0.87–1.01; distant recurrence: RR 0.92, 95% CI 0.85–0.99; and mortality: RR 0.91, 0.83–0.99) [ 24 ].
← all excerpts
Association between osteoporosis under treatment and all-cause and specific-cause mortalities: a nationwide retrospective cohort study in South Korea.
1
—
—